不同体液标本活检在肺癌微小残留疾病监测中的应用

• 作者： 闫星, 刘山梅, 刘长宏 ¹
• 作者单位：
  1.  大连医科大学附属第二医院内蒙古医科大学
• 提交时间：2022-09-13

摘要: 肺癌是世界致死率最高的恶性肿瘤之一，其主要难以攻克的原因就是治疗后复发。微小残留疾病（Minimal Residual Disease MRD）作为实体瘤复发的“桥头堡”，被描述为治疗原发肿瘤后，在没有任何癌症临床症状的情况下，患者的生物液体中仍然存在游离的循环肿瘤细胞或其他肿瘤细胞衍生物。近期中国也达成了首个“肺癌MRD的检测和临床应用共识”，旨在通过液体活检监测以评估其 MRD状态，进而完善肺癌患者术后个体化治疗。本文综述了几种热点液体（外周血、尿液、唾液、痰液、胸腔积液）标本在肺癌MRD检测中的进展, 并探讨其对指导肺癌MRD精准治疗的应用价值。

Abstract: Lung cancer is one of the world's deadliest cancers, and the main reason it's difficult to conquer is that it recurs after treatment. Minimal Residual Disease (MRD), as a "bridgehead" for the recurrence of solid tumors, is described as the presence of free circulating tumor cells or other tumor cell derivatives in the biologic fluid of patients without any clinical symptoms of cancer after the treatment of the primary tumor. Recently, China also reached the first "consensus on the detection and clinical application of lung cancer MRD", aiming to evaluate the MRD status through liquid biopsy monitoring, so as to improve the postoperative individualized treatment of lung cancer patients. This paper reviewed the progress of several hot fluids (peripheral blood, urine, saliva, sputum and pleural effusion) in the detection of lung cancer MRD, and discussed their application value in guiding the precise treatment of lung cancer MRD.

• 分类： 医学、药学 >> 基础医学
• 引用： ChinaXiv:202209.00113 (或此版本 ChinaXiv:202209.00113V1)
  DOI:10.12114/j.issn.1007-9572.2022.0641
  CSTR:32003.36.ChinaXiv.202209.00113.V1
• 推荐引用方式： 闫星, 刘山梅, 刘长宏.(2022).不同体液标本活检在肺癌微小残留疾病监测中的应用.中国全科医学.doi:10.12114/j.issn.1007-9572.2022.0641 (点此复制)